Tag archive for ‘biotechnology company’
Can-Fite is part of Israel startup nation

Can-Fite’s new Drug Fights Diabetes-Related Erectile Dysfunction

Israel’s Can-Fite BioPharma Ltd., a biotechnology company which develops proprietary small molecule drugs for treating cancer and inflammatory diseases, reported it has received positive data regarding More...

Jewish Business News On Monday, October 6th, 2014

Kadimastem Approached the FDA Regarding Its ALS Treatment

– The company recently reported positive results in its first pre-clinical trial for the treatment of ALS. – Israeli biotechnology company Kadimastem announces today that it approached the FDA regarding More...

Can-Fite is part of Israel startup nation
Gil Tanenbaum On Wednesday, October 1st, 2014

Can-Fite BioPharma Liver Drug Gets US Patent

Israel’s Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, has received a patent in the US for its More...

Gil Tanenbaum On Tuesday, September 30th, 2014

Altox Bio Gets $24 Million to Fight Flesh Eating Disease

Atox Bio, an Israeli a clinical stage biotechnology company, has been awarded a $24 million contract to fight flesh eating diseases. No, such diseases are not something out of the Walking Dead which could More...

Gil Tanenbaum On Tuesday, September 16th, 2014

Algatechnologies to Spend $17 Mill on More Astaxanthin

Israel’s Algatechnologies, a rapidly growing biotechnology company, specializing in the commercial cultivation of microalgae for food, medicines and cosmetics, will invest $17 million to double the More...

Jewish Business News On Sunday, August 3rd, 2014

Kadimastem to collaborate with Merck Serono

–   Israeli biotechnology company Kadimastem (TASE: KDST) has signed a collaboration agreement with Merck to carry out drug screening in the neurodegenerative diseases space for multiple sclerosis More...

Shiri Habib-Valdhorn On Wednesday, January 8th, 2014

Teva Offers $114 Million For Biotechnology company NuPathe

– In a notice to the SEC, biotech company NuPathe said that Teva is offering $3.65 per share, compared with yesterday’s closing price of $3.23. – The NuPathe migraine patch is worn on More...

Wordpress site Developed by Fixing WordPress Problems